| abstract |
Muscarinic receptor antagonists of formula (I), and their pharmaceutically acceptable salts, wherein Y is -CH2-, -(CH2)2-, -CH2O-, -(CH2)2O- or -CH2S-; R is -CN or -CONH2; and R1 is a group of formula (a), where R?2 and R3¿ are each independently H, C¿1?-C4 alkyl, C1-C4 alkoxy, -(CH2)nOH, halo, trifluoromethyl, cyano, -(CH2)nNR?4R5¿, -CO(C¿1?-C4 alkyl), -OCO(C1-C4 alkyl), -CH(OH)(C1-C4 alkyl), -C(OH)(C1-C4 alkyl)2, -SO2NH2, -(CH2)nCONR?6R7¿ or -(CH¿2?)nCOO(C1-C4 alkyl); R?4¿ is H or C¿1?-C4 alkyl; R?5¿ is H, C¿1?-C4 alkyl or C1-C4 alkylsulphonyl; R?6 and R7¿ are each independently H or C¿1?-C4 alkyl; and n is 0, 1 or 2. The compounds are particularly useful in treating irritable bowel syndrome. |